Eli Lilly’s Weight Loss Drug, Tirzepatide, Shows Promising Phase 3 Results: If Approved, Next Hurdle Would Be Reimbursement

Eli Lilly’s weight loss drug, tirzepatide, showed substantial potential in a large Phase 3 study, the results of which were reported on April 28th. If tirzepatide gets approved, it could become a blockbuster. But, this isn’t a sure thing. It will have to overcome pricing and reimbursement obstacles.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive